share_log

10-Q: Q1 2024 Earnings Report

10-Q: Q1 2024 Earnings Report

10-Q：2024財年一季報
美股sec公告 ·  05/14 16:10
Moomoo AI 已提取核心訊息
Conduit Pharmaceuticals Inc. (Conduit) reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $3.6 million, compared to a net loss of $1.7 million in the same period the previous year. Research and development expenses were $128,000, attributed to the development of co-crystals of AZD1656, a compound targeting autoimmune diseases. General and administrative expenses increased by 87% to $2.8 million, primarily due to higher salaries and stock compensation expense, as well as insurance-related costs. Other income and expenses resulted in a net expense of $597,000, mainly due to the issuance of warrants. Interest expense was reported at $119,000. Conduit's cash flow from operating activities was a net use of $2.4 million. The company did not engage in investing activities and had no cash flow from financing activities for the quarter. Conduit's management is seeking additional capital to fund operations and continue as a going concern. The company's future plans include advancing clinical assets through development and seeking partnerships for licensing opportunities.
Conduit Pharmaceuticals Inc. (Conduit) reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $3.6 million, compared to a net loss of $1.7 million in the same period the previous year. Research and development expenses were $128,000, attributed to the development of co-crystals of AZD1656, a compound targeting autoimmune diseases. General and administrative expenses increased by 87% to $2.8 million, primarily due to higher salaries and stock compensation expense, as well as insurance-related costs. Other income and expenses resulted in a net expense of $597,000, mainly due to the issuance of warrants. Interest expense was reported at $119,000. Conduit's cash flow from operating activities was a net use of $2.4 million. The company did not engage in investing activities and had no cash flow from financing activities for the quarter. Conduit's management is seeking additional capital to fund operations and continue as a going concern. The company's future plans include advancing clinical assets through development and seeking partnerships for licensing opportunities.
Conduit Pharmaceuticals公司（Conduit）報告了截至2024年3月31日的財務業績。公司淨虧損360萬美元，與去年同期170萬美元的淨虧損相比有所增加。研發費用爲128,000美元，用於開發針對自身免疫性疾病的AZD1656共晶的化合物。一般管理費用增長了87％至280萬美元，主要是由於更高的薪水和股票補償費用以及保險相關成本。其他收入和費用導致淨費用爲597,000美元，主要是由於授予認股權所致。利息支出爲119,000美元。Conduit的經營活動現金流爲淨使用240萬美元。公司未進行投資活動，並且該季度沒有籌資活動的現金流量。Conduit的管理層正在尋求額外的資金來資助運營並繼續作爲一個運營單位。公司的未來計劃包括推進臨床資產的開發，並尋求授權機會的合作伙伴。
Conduit Pharmaceuticals公司（Conduit）報告了截至2024年3月31日的財務業績。公司淨虧損360萬美元，與去年同期170萬美元的淨虧損相比有所增加。研發費用爲128,000美元，用於開發針對自身免疫性疾病的AZD1656共晶的化合物。一般管理費用增長了87％至280萬美元，主要是由於更高的薪水和股票補償費用以及保險相關成本。其他收入和費用導致淨費用爲597,000美元，主要是由於授予認股權所致。利息支出爲119,000美元。Conduit的經營活動現金流爲淨使用240萬美元。公司未進行投資活動，並且該季度沒有籌資活動的現金流量。Conduit的管理層正在尋求額外的資金來資助運營並繼續作爲一個運營單位。公司的未來計劃包括推進臨床資產的開發，並尋求授權機會的合作伙伴。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息